Blueprint Medicines Cash Flow from Financial Activities 2014-2025 | BPMC

Blueprint Medicines cash flow from financial activities for the twelve months ending March 31, 2025 was $0.791B, a 167.84% increase year-over-year.

  • Blueprint Medicines annual cash flow from financial activities for 2024 was $0.273B, a 129.07% increase from 2023.
  • Blueprint Medicines annual cash flow from financial activities for 2023 was $0.119B, a 78.78% decline from 2022.
  • Blueprint Medicines annual cash flow from financial activities for 2022 was $0.562B, a 1007.76% increase from 2021.

Blueprint Medicines Cash Flow from Financial Activities 2014-2025 | BPMC

  • Blueprint Medicines annual cash flow from financial activities for 2024 was $0.273B, a 129.07% increase from 2023.
  • Blueprint Medicines annual cash flow from financial activities for 2023 was $0.119B, a 78.78% decline from 2022.
  • Blueprint Medicines annual cash flow from financial activities for 2022 was $0.562B, a 1007.76% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$225.3B
Amgen (AMGN)$164.8B
Gilead Sciences (GILD)$144.5B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$98.6B
CSL (CSLLY)$85.4B
GSK (GSK)$77.5B
Regeneron Pharmaceuticals (REGN)$60.8B
Alnylam Pharmaceuticals (ALNY)$42.9B
Argenex SE (ARGX)$36.2B
BioNTech SE (BNTX)$27.7B
Royalty Pharma (RPRX)$20.6B
Insmed (INSM)$19.7B
Biogen (BIIB)$19.3B
Illumina (ILMN)$17.3B
Genmab (GMAB)$15B
Genmab (GNMSF)$15B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.2B
Exelixis (EXEL)$12.4B
QIAGEN (QGEN)$11.5B
BioMarin Pharmaceutical (BMRN)$11.3B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.2B
Bio-Techne Corp (TECH)$9.2B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$9B
Legend Biotech (LEGN)$8B
Roivant Sciences (ROIV)$7.9B
Regencell Bioscience Holdings (RGC)$7.4B